NEOPHORE LIMITED
From public filings as at 31 Aug 2026; may contain errors or be out of date. Verify at Companies House · Terms
Watch this company
Get an email when Companies House records a change for Neophore Limited: status, filings, accounts, officers or owners. Free.
Not live yet: alerts start by 15 December 2026. We store your email and this company number only, for these alerts. If alerts don’t launch, we tell you and delete your address. Privacy
What does Neophore Limited sell?
Registered activity: Research and experimental development on biotechnology (SIC 72110). We’re building product and service lists for UK companies. Get this one when it’s ready.
Summary
NEOPHORE LIMITED is an active private limited company (company number 10762171) incorporated on 9 May 2017, registered in Altrincham. Its registered activity is research and experimental development on biotechnology (SIC 72110). Latest small accounts cover the period ending 31 March 2026, showing net assets of £4.20m and cash of £4.07m, with 14 employees on average. Net assets fell 54% on the prior period (£9.14m).
By net assets it sits in the top quarter of 138 comparable companies in Manchester (median £436, upper quartile £124k).
Ownership and control
No active person with significant control is registered.
- Jeffrey James Roix
- owns 25–50% of shares
- holds 25–50% of voting rights
- Dr Christopher John Torrance
- owns 25–50% of shares
- holds 25–50% of voting rights
- Crt Pioneer Gp Limited
- owns 25–50% of shares
- holds 25–50% of voting rights
Persons with significant control hold 25% or more of shares or voting rights. Smaller shareholdings are only listed in confirmation-statement documents. Directors and secretaries: see the officers list at Companies House.
Key dates
- Incorporated
- 9 May 20179 yrs ago
- Next accounts due
- 31 December 2027in 430 days
- Confirmation statement due
- 23 May 2027in 208 days
Due dates are expected from Companies House filing rules; confirm on the official register before relying on them.
Activity
- SIC 72110
- Research and experimental development on biotechnology
- Accounts type
- Small
- Size band
- SmallCompanies Act thresholds
Financials
| Period end | Net assets | Cash | Debtors | Creditors <1y | Turnover | Profit | Employees |
|---|---|---|---|---|---|---|---|
| 31 March 2026 | £4.20m | £4.07m | — | £1.09m | — | −£4.94m | 14 |
| 31 March 2025 | £9.14m | £9.11m | — | £1.47m | — | −£7.02m | 10 |
| 1 April 2024 | — | — | — | — | — | — | — |
Figures as filed in iXBRL accounts at Companies House. "—" means the line was not reported in that filing.
Filing and accounts signals
- Net assets above zeroNet assets £4,198,834 at 31 March 2026
- Net assets down 25% or more on the prior period-54.1% vs prior period
- Current assets at least 1.5× creditors within one yearCurrent ratio 4.67
- Cash at bank of £50,000 or moreCash £4,069,425
- Three or more accounting periods on record3 periods on record
- Incorporated five or more years agoIncorporated 9 May 2017
Neutral facts read from the register and filed accounts, each with its evidence. They are not a rating, a prediction or advice, and may be incomplete or out of date. How each signal is derived.
Timeline
- Next accounts duein 430 days
- Confirmation statement duein 208 days
- Accounts period endNet assets £4.20m · small accounts
- Accounts period endNet assets £9.14m · small accounts
- Accounts period end
- Incorporated
Similar companies in Manchester
- HAIRCLONE CELL THERAPY LIMITEDManchester · inc. Jun 2017
- HAIRCLONE RESEARCH LIMITEDManchester · inc. Jun 2017
- DARESBURY PROTEINS LTD.Warrington · inc. Jun 2017
- HAIRCLONE CELL BANKING LIMITEDManchester · inc. Aug 2017
- CANCERTAIN LIMITEDCheadle · inc. Jan 2017
- EVARISTE LTDAltrincham · inc. Oct 2017
All companies incorporated on 9 May 2017 · in May 2017.
Reminders for NEOPHORE LIMITED
Get an email before each filing deadline — accounts and confirmation statement — so nothing is late.